ERBB2 and neoplasm: However, in clinical practice, it is difficult for us to assess tumor HER2 expression status in real time through multiple pre-operative multi-site CNB, and pre-operative CNB are difficult to circumvent the potential bias caused by intra-tumoral heterogeneity of HER2.Therefore, it is difficult to achieve clinical real-time detection and evaluation and individualized treatment.